Introduction {#sec1}
============

Cancer, although an age old disease, still poses a formidable challenge to researchers and clinicians. Little is known about its initiation, sustenance, progression and metastasis, and resistance and remission. Due to its morbidity and mortality, cancer is one of the most dreaded diseases and the related fatalities are majorly attributed to delayed diagnosis and treatment. Head and neck cancer (HNC), the sixth most frequent kind of cancer worldwide, is a group of biologically similar cancers that originate from head and neck regions such as oral cavity, pharyngeal cavity, and larynx \[[@B1]\]. Multifactors such as smoking, drinking, betel quid chewing, papilloma virus infection, and exposure to toxic substances are suggested to be the etiological risk factors for HNC \[[@B2],[@B3]\]. Nevertheless, though many individuals are exposed to these external factors, HNC develops only in a small proportion of the exposed people, indicating that intrinsic factors such as genetic polymorphism might play critical roles in its carcinogenic mechanisms.

miRNAs represent a class of evolutionarily conserved, endogenous, single-stranded, non-coding RNA molecules of \~20 nts that regulate gene expression by degrading mRNAs or suppressing translation. miRNAs have been implicated in a wide range of physiologic and pathologic processes, including development, cell differentiation, proliferation, apoptosis, and carcinogenesis \[[@B4],[@B5]\]. Accumulating evidence indicates that the expression of roughly 10--30% of all human genes is regulated by miRNAs \[[@B6]\]. More than half of the known miRNAs are located in cancer-associated genomic regions, and miRNAs are thought to contribute to oncogenesis because they can function either as tumor suppressors or oncogenes \[[@B7]\]. Analyses in human epithelial malignancies have shown that cancers can be distinguished and classified by distinct tumor-specific miRNA signatures \[[@B8]\]. Some of the key dysregulated miRNAs could serve as molecular biomarkers, leading to improved diagnosis and monitoring of cancer treatment response \[[@B9]--[@B11]\].

Single nucleotide polymorphisms (SNPs) are a type of common genetic variations associated with population diversity, disease susceptibility, drug metabolism, and genome evolution \[[@B12]\]. SNPs may affect the expression and function of miRNAs, which could therefore contribute to the susceptibility to cancer occurrence and development \[[@B13]--[@B16]\]. *miR-146a* C/G is located in the stem region opposite to the mature *miR-146a* sequence, which is suspected to have an effect on tumor immune responses and ultimately the development of cancer. In recent years, the polymorphism rs2910164 in *miR-146a* has attracted wide attention and many studies have been published to explore the association between SNPs of miRNAs and susceptibility to various cancers. But the results were not conclusive and consistent. Since SNPs in miRNAs are closely associated with head and neck cancer (HNC) susceptibility, it is necessary to assess whether these SNP polymorphisms are the risk factors for HNC. It is reported that meta-analysis is a well-established method for combining all the results from the available published information to produce a single estimate for quantitating gene--disease associations more precisely to increase the statistical power \[[@B17]\]. Thus, we performed this meta-analysis of case--control studies to estimate the importance of pre-*miR-146a* C/G polymorphism for HNC susceptibility.

Materials and methods {#sec2}
=====================

Publication search {#sec2-1}
------------------

A comprehensive electronic search was performed to identify articles published up until 12 November 2016 in MEDLINE (mainly PubMed), Embase, the Cochrane Library, and Google Scholar using the following search terms: '*miR-146a*' or 'rs2910164' and 'head and neck cancer' or 'cancer' or 'tumor' or 'carcinoma' and 'polymorphism' or 'SNPs' or 'variation'. All eligible studies published in English were retrieved, and their bibliographies were checked for additional relevant publications. Review articles and bibliographies of other identified relevant studies were searched by hand to identify any additional eligible studies.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Studies included in this meta-analysis had to meet all of the following criteria: (i) case--control study evaluating the association between *miR-146a* C/G polymorphism and susceptibility to HNC and overall cancer; (ii) sufficient published data for calculating odds ratios (ORs) with corresponding 95% confidence intervals (CIs); (iii) full-text manuscript; and (iv) only the most recent or complete study reporting on the same population of patients was included. Exclusion criteria included: (i) reviews, other meta-analyses, comments, letters, and editorial articles; (ii) not a case--control study; and (iii) no usable data reported.

Data extraction {#sec2-3}
---------------

Information regarding the following aspects was independently retrieved from each study by two reviewers: the first author's surname, year of publication, country of origin, ethnicity, study design, total number of cases and controls, source of cases and controls, detected sample, genotyping methods, allele and genotype frequencies of cases and controls, and evidence of Hardy--Weinberg equilibrium (HWE) in the controls. In studies including subjects of more than one ethnicity, genotype data were extracted separately for each ethnic group. Data from one publication may contain more than one seperate case-control studies. Any discrepancies between the reviewers were resolved through discussion to reach a consensus.

Statistical analysis {#sec2-4}
--------------------

We used crude ORs with 95% CIs to explore the association between *miR-146a* C/G polymorphism and the risk of HNC and overall cancer. Five genetic variation models were analyzed: homozygote model (CC compared with GG), heterogeneity model (GC compared with CC), dominant model (CC + GC compared with GG), recessive model (CC compared with GC + GG), and allele comparison model (C compared with G). *P*-value of HWE in control group of each study was calculated by *χ*^2^ test and *P*\<0.05 presented a state of disequilibrium \[[@B18]\]. We also performed subgroup analyses by ethnicity and source of control, and heterogeneity was calculated by *χ*^2^-based Q-statistic \[[@B19]\]. Both random-effects model (when *P*-value of heterogeneity was less than 0.05) and fixed-effects model (when *P*-value of heterogeneity was more than 0.05) were used \[[@B20],[@B21]\]. Sensitivity analyses were performed to verify if our present results were stable. Begg's funnel plots and Egger's linear regression tests were used to examine possible publication bias \[[@B22],[@B23]\]. All statistical analyses were performed using Stata software version 11.0 (StataCorp LP, College Station, TX, U.S.A.). All statistical analyses were two-sided, and *P*-values \<0.05 were considered statistically significant.

Results {#sec3}
=======

Characteristics of eligible studies {#sec3-1}
-----------------------------------

A total of 721 articles were retrieved after the first search in PubMed, Embase, the Cochrane Library, and Google Scholar. Selection following the specified criteria eliminated 632 studies, leaving 89 individual studies \[[@B24]--[@B103]\]. The details of the selection process are presented in [Figure 1](#F1){ref-type="fig"}. The publication years of included articles ranged from 2008 to 2016. The distributions of *miR-146a* C/G genotype in all studies were in accordance with HWE in the control group. No significant differences were found between cases and controls with respect to gender and age distributions. The modified quality scores of all studies ranged from 9 to 16, with 71% (5/7) of the included studies classified as high quality (≥12).The characteristics of all included studies are summarized in [Table 1](#T1){ref-type="table"}.

![The process of literature research](bsr-38-bsr20171342-g1){#F1}

###### Characteristics of all eligible studies

  Reference                         Year   Country                      Ethnicity   Cancer type                 Control source   Genotyping method                         Sample size   Case   Control                            
  --------------------------------- ------ ---------------------------- ----------- --------------------------- ---------------- ----------------------------------------- ------------- ------ --------- ----- ----- ----- ------ ------
  Horikawa et al. \[[@B24]\]        2008   U.S.A.                       Caucasian   Renal cell cancer           PB               SNPlex assay                              261           235    144       103   14    126   94     15
  Jazdzewski et al.^1^ \[[@B25]\]   2008   Finland                      Caucasian   PTC                         PB               SNPlex assay                              206           274    99        104   3     150   105    19
  Jazdzewski et al.^2^ \[[@B25]\]   2008   Poland                       Caucasian   PTC                         PB               SNPlex assay                              201           475    115       82    4     286   163    26
  Jazdzewski et al.^3^ \[[@B25]\]   2008   U.S.A.                       Caucasian   PTC                         PB               SNPlex assay                              201           152    91        101   9     90    52     10
  Xu et al. \[[@B26]\]              2008   China                        Asian       Liver cancer                HB               PCR-RFLP                                  479           504    80        241   158   58    249    197
  Yang et al. \[[@B27]\]            2008   U.S.A.                       Caucasian   Bladder cancer              PB               SNPlex assay                              691           674    414       242   35    385   258    31
  Hoffman et al. \[[@B28]\]         2009   U.S.A.                       Caucasian   Breast cancer               PB               massARRAY                                 439           478    234       176   29    273   178    27
  Hu et al. \[[@B29]\]              2009   China                        Asian       Breast cancer               HB               PCR-RFLP                                  1009          1093   165       515   329   180   551    362
  Tian et al. \[[@B30]\]            2009   China                        Asian       Lung cancer                 PB               PCR-RFLP                                  1058          1035   360       510   188   364   502    169
  Catucci et al.^1^ \[[@B31]\]      2010   Italy                        Caucasian   Breast cancer               HB               Sequencing                                754           1243   409       286   59    650   520    73
  Catucci et al.^2^ \[[@B31]\]      2010   Germany                      Caucasian   Breast cancer               HB               Sequencing                                805           904    451       304   50    536   318    50
  Guo et al. \[[@B32]\]             2010   China                        Caucasian   ESCC                        PB               SNaPshot                                  444           468    234       190   20    206   220    42
  Liu et al. \[[@B33]\]             2010   U.S.A.                       Mixed       SCCHN                       HB               PCR-RFLP                                  1109          1130   630       411   68    655   405    70
  Okubo et al. \[[@B34]\]           2010   Japan                        Asian       Gastric cancer              HB               PCR-RFLP                                  552           697    73        243   236   121   322    254
  Pastrello et al. \[[@B35]\]       2010   Italy                        Caucasian   Breast and ovarian cancer   PB               Sequencing                                101           155    60        36    5     90    59     6
  Srivastava et al. \[[@B36]\]      2010   India                        Asian       Gall bladder cancer         PB               PCR-RFLP                                  230           224    129       90    11    138   81     5
  Xu et al. \[[@B37]\]              2010   China                        Asian       Prostate cancer             HB               PCR-RFLP                                  251           280    68        135   48    54    150    76
  Zeng et al. \[[@B38]\]            2010   China                        Asian       Gastric cancer              HB               PCR-RFLP                                  304           304    62        153   89    53    132    119
  Akkiz et al. \[[@B39]\]           2011   Turkey                       Caucasian   Liver cancer                HB               PCR-RFLP                                  222           222    137       75    10    144   67     11
  Garcia et al. \[[@B40]\]          2011   French                       Caucasian   Breast cancer               PB               TaqMan                                    1130          596    676       388   66    352   220    24
  George et al. \[[@B41]\]          2011   India                        Asian       Prostate cancer             PB               PCR-RFLP                                  159           230    4         79    76    7     107    116
  Hishida et al. \[[@B42]\]         2011   Japan                        Asian       Gastric cancer              HB               PCR-RFLP                                  583           1637   82        271   230   229   775    633
  Mittal et al. \[[@B43]\]          2011   India                        Asian       Bladder cancer              PB               PCR-RFLP                                  212           250    127       79    6     135   108    7
  Permuth-Wey et al. \[[@B44]\]     2011   U.S.A.                       Caucasian   Glioma                      PB               GoldenGate                                593           614    345       198   50    375   214    25
  Vinci et al. \[[@B45]\]           2011   Italy                        Caucasian   NSCLC                       PB               HRMA                                      101           129    44        48    9     73    45     11
  Yue et al. \[[@B46]\]             2011   China                        Asian       Cervical cancer             HB               PCR-RFLP                                  447           443    118       224   105   87    206    150
  Zhang et al. \[[@B47]\]           2011   China                        Asian       Liver cancer                HB               PIRA-PCR                                  925           1593   156       450   319   291   725    577
  Zhou et al. \[[@B48]\]            2011   China                        Asian       CSCC                        HB               PCR-RFLP                                  226           309    43        113   70    34    159    116
  Ma et al. \[[@B49]\]              2012   China                        Asian       Gastric cancer              HB               Sequencing                                86            42     20        44    14    6     19     14
  Alshatwi et al. \[[@B50]\]        2012   Saudi                        Asian       Breast cancer               PB               TaqMan                                    100           100    2         50    48    3     46     51
  Chu et al. \[[@B51]\]             2012   China                        Asian       Oral cancer                 HB               PCR-RFLP                                  470           425    54        242   174   54    196    175
  Hezova et al. \[[@B52]\]          2012   Czech                        Caucasian   Colorectal                  HB               TaqMan                                    197           212    115       70    12    124   79     9
  Kim et al. \[[@B53]\]             2012   Korea                        Asian       Liver cancer                PB               PCR-RFLP                                  286           201    27        159   100   24    103    74
  Lung et al. \[[@B54]\]            2012   China                        Asian       Nasopharyngeal carcinoma    PB               Tm-shift                                  229           3631   24        88    117   497   1721   1413
  Mihalache et al. \[[@B55]\]       2012   Italy and Germany            Caucasian   Cholangiocarcinoma          HB               TaqMan                                    182           350    118       53    11    211   122    17
  Min et al. \[[@B56]\]             2012   Korea                        Asian       Colorectal                  HB               PCR-RFLP                                  446           502    62        233   151   69    245    188
  Wang et al. \[[@B57]\]            2012   China                        Asian       Bladder cancer              HB               TaqMan                                    1017          1179   369       456   192   340   571    268
  Xiang et al. \[[@B58]\]           2012   China                        Asian       Liver cancer                HB               PCR-RFLP                                  100           200    27        45    28    45    100    55
  Zhou et al. \[[@B59]\]            2012   China                        Asian       Liver cancer                PB               PCR-RFLP                                  186           483    33        86    67    71    254    158
  Zhou et al. \[[@B60]\]            2012   China                        Asian       Gastric cancer              HB               TaqMan                                    1686          1895   578       822   286   551   951    393
  Lv et al. \[[@B61]\]              2013   China                        Asian       Colorectal cancer           PB               PCR-RFLP                                  353           540    54        230   47    96    274    143
  Chae et al. \[[@B62]\]            2013   Korea                        Asian       Colorectal cancer           PB               PCR-RFLP                                  399           568    61        182   156   121   282    165
  Ma et al. \[[@B63]\]              2013   China                        Asian       TNBC                        HB               massARRAY                                 192           191    35        94    63    34    93     64
  Ma et al. \[[@B64]\]              2013   China                        Asian       Colorectal cancer           HB               TaqMan                                    1147          1203   444       534   169   397   614    192
  Orsos et al. \[[@B65]\]           2013   Hungary                      Caucasian   SCCHN                       PB               PCR-RFLP                                  468           468    284       168   16    323   136    9
  Vinci et al. \[[@B66]\]           2013   Italy                        Caucasian   Colorectal cancer           PB               HRMA                                      160           178    86        57    17    100   65     13
  Wei et al. \[[@B67]\]             2013   China                        Asian       PTC                         PB               massARRAY                                 753           760    136       323   294   138   345    277
  Wei et al. \[[@B68]\]             2013   China                        Asian       ESCC                        HB               massARRAY                                 368           370    67        184   117   67    181    122
  Yamashita et al. \[[@B69]\]       2013   Japan                        Asian       Melanoma                    PB               PCR-RFLP                                  50            107    0         35    15    3     53     51
  Zhang et al. \[[@B70]\]           2013   China                        Asian       HCC                         PB               MassARRAY                                 997           998    163       503   331   156   475    367
  Ahn et al. \[[@B71]\]             2013   Korea                        Asian       Gastric cancer              HB               PCR-RFLP                                  461           447    71        231   159   62    221    164
  Song et al. \[[@B72]\]            2013   China                        Asian       Gastric cancer              HB               PCR-RFLP                                  1208          1166   199       586   423   207   615    344
  Wu \[[@B73]\]                     2014   China                        Asian       Colorectal cancer           HB               ASA                                       175           300    22        59    80    53    120    114
  Chu et al. \[[@B74]\]             2014   China                        Asian       HCC                         HB               PCR-RFLP                                  188           337    22        82    84    50    145    141
  Cong et al. \[[@B75]\]            2014   China                        Asian       HCC                         HB               PCR-RFLP                                  206           218    27        85    94    17    84     117
  Dikeakos et al. \[[@B76]\]        2014   Greece                       Caucasian   Gastric cancer              HB               PCR-RFLP                                  163           480    13        45    105   24    149    307
  Du et al. \[[@B77]\]              2014   China                        Asian       Renal                       HB               TaqMan assay                              353           362    68        167   118   57    190    115
  Hu et al. \[[@B78]\]              2014   China                        Asian       Colorectal                  HB               PCR-RFLP                                  200           373    34        82    84    44    187    142
  Huang et al. \[[@B79]\]           2014   China                        Asian       Nasopharyngeal              HB               PCR-RFLP                                  160           200    23        73    64    36    110    54
  Jeon et al. \[[@B80]\]            2014   Korea                        Asian       Lung                        PB               PCR-RFLP                                  1091          1096   223       500   368   244   540    312
  Jia et al. \[[@B81]\]             2014   China                        Asian       NSCLC                       HB               PCR-RFLP                                  400           400    64        182   154   76    200    124
  Kupcinskas et al. \[[@B82]\]      2014   Germany, Lithuania, Latvia   Caucasian   Gastric                     HB               TaqMan assay                              362           347    252       94    16    223   108    16
  Kupcinskas et al. \[[@B83]\]      2014   Lithuania, Latvia            Caucasian   Colorectal                  HB               TaqMan assay                              192           424    140       50    2     275   134    15
  Mao et al. \[[@B84]\]             2014   China                        Asian       Colorectal                  PB               SNPscan system                            547           561    70        291   186   85    271    205
  Nikolić et al. \[[@B85]\]         2014   Serbia                       Caucasian   Prostate                    HB               TaqMan assay                              286           199    184       90    12    129   63     7
  Palmieri et al.^1^ \[[@B86]\]     2014   Italy                        Caucasian   OSCC                        HB               TaqMan assay                              337           88     197       121   19    50    31     7
  Palmieri et al.^2^ \[[@B86]\]     2014   Italy                        Caucasian   OSCC                        HB               TaqMan assay                              337           206    197       121   19    105   84     17
  Palmieri et al.^3^ \[[@B86]\]     2014   Italy                        Caucasian   OSCC                        HB               TaqMan assay                              337           543    197       121   19    297   206    40
  Parlayan et al.^1^ \[[@B87]\]     2014   Japan                        Asian       Gastric                     HB               TaqMan assay                              160           524    20        79    61    71    237    216
  Parlayan et al.^2^ \[[@B87]\]     2014   Japan                        Asian       Lung                        HB               TaqMan assay                              148           524    25        67    56    71    237    216
  Parlayan et al.^3^ \[[@B87]\]     2014   Japan                        Asian       Prostate                    HB               TaqMan assay                              89            524    11        41    37    71    237    216
  Pu et al. \[[@B88]\]              2014   China                        Asian       Gastric                     HB               PCR-RFLP                                  197           513    36        96    65    96    274    143
  Qu et al. \[[@B89]\]              2014   China                        Asian       ESCC                        HB               Allele-specific PCR                       381           426    62        203   116   75    228    123
  Dikaiakos et al. \[[@B90]\]       2015   Greece                       Caucasian   Colorectal                  HB               PCR-RFLP                                  157           299    8         48    101   21    120    158
  Gomez-Lira et al. \[[@B91]\]      2015   Italy                        Caucasian   Melanoma                    HB               PCR-RFLP                                  224           264    107       100   17    149   105    10
  Qi et al. \[[@B92]\]              2015   China                        Asian       Breast cancer               PB               PCR-RFLP                                  321           290    146       132   43    126   144    20
  Zhu et al. \[[@B93]\]             2015   China                        Asian       ESCC                        HB               PCR-RFLP                                  248           300    82        120   36    99    139    40
  Deng et al. \[[@B94]\]            2015   China                        Asian       Bladder cancer              HB               PCR-RFLP                                  159           258    26        73    60    32    154    112
  Li et al. \[[@B95]\]              2015   China                        Asian       HCC                         HB               PCR-RFLP                                  266           266    151       86    29    166   81     19
  Shen et al. \[[@B96]\]            2015   China                        Asian       ESCC                        HB               SNaPshot multiplex system                 1400          2185   220       685   495   345   1060   780
  Yan et al. \[[@B97]\]             2015   China                        Asian       HCC                         HB               PCR-RFLP                                  274           328    35        145   94    36    169    123
  Yin et al. \[[@B98]\]             2015   China                        Asian       Lung cancer                 HB               PCR-RFLP                                  575           608    97        280   198   127   313    168
  Xia et al. \[[@B99]\]             2015   China                        Asian       Gastric cancer              HB               TaqMan assay                              1125          1196   192       536   397   199   577    420
  Hashemi et al. \[[@B100]\]        2016   Iran                         Caucasian   Prostate cancer             HB               T-ARMS-PCR assay                          169           182    25        131   13    24    147    11
  Jiang et al. \[[@B101]\]          2016   China                        Asian       Gastric cancer              HB               MassARRAY                                 898           992    154       441   303   207   457    325
  Miao et al. \[[@B102]\]           2016   China                        Asian       HNSCC                       HB               Illumina Infinium1 human exome BeadChip   576           1552   497       773   278   154   228    80
  Chen et al.^1^ \[[@B103]\]        2016   Taiwan                       Asian       OSCC                        HB               TaqMan assay                              512           668    71        241   200   103   293    272
  Chen et al.^2^ \[[@B103]\]        2016   Taiwan                       Asian       PSCC                        HB               TaqMan assay                              146           668    16        77    53    103   293    272
  Chen et al.^3^ \[[@B103]\]        2016   Taiwan                       Asian       OPSCC                       HB               TaqMan assay                              658           668    87        318   253   103   293    272

Abbreviations: BC, breast cancer; CRC, colorectal cancer; GC, gastric cancer; ESCC,esophageal squamous cell carcinoma; HB, hospital-based; HCC, hepatocellular carcinoma; HNSCC, squamous cell carcinoma of the head and neck; HRMA, high resolution melting analysis; LC, lung cancer; NSCLC, non-small-cell lung carcinoma; OPSCC, squamous cell carcinoma of the oral cavity, oropharynx, and hypopharynx; OSCC, oral squamous cell carcinoma; PB, population-based; *P*~hwe~, *P*-value of HWE; PSCC, squamous cell carcinoma of the oropharynx and hypopharynx; PTC, papillary thyroid cancer; RFLP, restriction fragment length polymorphism; SCCHN, squamous cell carcinoma of head and neck; TNBC, triple negative breast cancer.

^1,2,3^The superscript values 1, 2 and 3, indicate the number of studies (one, two and three respectively) covered the published article.

*miR-146a* C/G polymorphism and HNC risk {#sec3-2}
----------------------------------------

In the overall analysis, we pooled 13 separate studies to explore the association between *miR-146a* C/G polymorphism and the risk of HNC under homozygote, heterozygote, recessive, and allele comparison model. There is no significant association between *miR-146a* C/G polymorphism and the risk of HNC under homozygote model (*I*^2^ =21.6%, *P*~heterogeneity~=0.226, OR =1.113, 95% CI =0.980--1.263, *P*=0.099, [Figure 2](#F2){ref-type="fig"}), heterozygote model (*I*^2^ =14.2%, *P*~heterogeneity~=0.301, OR =1.084, 95% CI =0.991--1.186, *P*=0.079, [Figure 3](#F3){ref-type="fig"}), recessive model (*I*^2^ =66.3%, *P*~heterogeneity~\<0.01, OR =1.068, 95% CI =0.896--1.272, *P*=0.465, [Figure 4](#F4){ref-type="fig"}), and allele comparison model (*I*^2^ =61%, *P*~heterogeneity~=0.002, OR =1.061, 95% CI =0.966--1.166, *P*=0.214, [Figure 5](#F5){ref-type="fig"}). Furthermore, we pooled all 14 eligible studies to explore the association between pre-*miR-146a* C/G polymorphism and the risk of HNC. Significant association was found under dominant model (*I*^2^ =15.6%, *P*~heterogeneity~=0.282, OR =1.088, 95% CI =1.002--1.182, *P*=0.044, [Figure 6](#F6){ref-type="fig"}). In the subgroup analysis by ethnicity, no significant association was found amongst Caucasians under homozygote model (*I*^2^ =36.7%, *P*~heterogeneity~=0.177, OR =0.919, 95% CI =0.716--1.180, *P*=0.509, [Table 2](#T2){ref-type="table"}), heterozygote model (*I*^2^ =52.7%, *P*~heterogeneity~=0.076, OR =1.040, 95% CI =0.922--1.173, *P*=0.521, [Table 2](#T2){ref-type="table"}), dominant model (*I*^2^ =58.6%, *P*~heterogeneity~=0.034, OR =1.027, 95% CI =0.857--1.232, *P*=0.772, [Table 2](#T2){ref-type="table"}), recessive model (*I*^2^ =10.9%, *P*~heterogeneity~=0.344, OR =0.919, 95% CI =0.719--1.174, *P*=0.449, [Table 2](#T2){ref-type="table"}), and allele comparison model (*I*^2^ =69%, *P*~heterogeneity~=0.012, OR =0.981, 95% CI =0.814--1.183, *P*=0.843, [Table 2](#T2){ref-type="table"}). Simultaneously, no associations were detected amongst Asians under heterozygote model (*I*^2^ =0, *P*~heterogeneity~=0.713, OR =1.142, 95% CI =0.997--1.308, *P*=0.054, [Table 2](#T2){ref-type="table"}), recessive model (*I*^2^ =76.5, *P*~heterogeneity~\<0.01, OR =1.133, 95% CI =0.914--1.404, *P*=0.254, [Table 2](#T2){ref-type="table"}), and allele comparison model (*I*^2^ =57.6, *P*~heterogeneity~=0.021, OR =1.103, 95% CI =0.988--1.233, *P*=0.082, [Table 2](#T2){ref-type="table"}), while slight association was found amongst Asians under homozygote model (*I*^2^ =0, *P*~heterogeneity~=0.541, OR =1.189, 95% CI =1.025--1.378, *P*=0.022, [Table 2](#T2){ref-type="table"}) and dominant model (*I*^2^ =0, *P*~heterogeneity~=0.959, OR =1.155, 95% CI =1.016--1.312, *P*=0.028, [Table 2](#T2){ref-type="table"}). In the stratified analysis by source of controls, a significantly increased cancer risk amongst population-based studies was found under homozygote model (*I*^2^ =0, *P*~heterogeneity~=0.855, OR =1.668, 95% CI =1.183--2.352, *P*=0.004, [Table 2](#T2){ref-type="table"}), dominant model (*I*^2^ =0, *P*~heterogeneity~=0.674, OR =1.359, 95% CI =1.095--1.687, *P*=0.005, [Table 2](#T2){ref-type="table"}), recessive model (*I*^2^ =0, *P*~heterogeneity~=0.874, OR =1.697, 95% CI =1.367--2.107, *P*\<0.001, [Table 2](#T2){ref-type="table"}), and allele comparison model (*I*^2^ =0, *P*~heterogeneity~=0.991, OR =1.394, 95% CI =1.215--1.599, *P*\<0.001, [Table 2](#T2){ref-type="table"}), while no association was found amongst population-based studies under heterozygote model (*I*^2^ =3.5%, *P*~heterogeneity~=0.408, OR =1.219, 95% CI =0.974--1.526, *P*=0.083, [Table 2](#T2){ref-type="table"}). Meanwhile, no significant association was found amongst hospital-based studies under homozygote model (*I*^2^ =0, *P*~heterogeneity~=0.471, OR =1.113, 95% CI =0.980--1.263, *P*=0.603, [Table 2](#T2){ref-type="table"}), heterozygote model (*I*^2^ =40.5%, *P*~heterogeneity~=0.186, OR =1.060, 95% CI =0.961--1.169, *P*=0.248, [Table 2](#T2){ref-type="table"}), dominant model (*I*^2^ =0, *P*~heterogeneity~=0.462, OR =1.047, 95% CI =0.957--1.144, *P*=0.318, [Table 2](#T2){ref-type="table"}), recessive model (*I*^2^ =26%, *P*~heterogeneity~=0.204, OR =0.941, 95% CI =0.849--1.043, *P*=0.247, [Table 2](#T2){ref-type="table"}), and allele comparison model (*I*^2^ =19.8%, *P*~heterogeneity~=0.261, OR =0.994, 95% CI =0.935--1.056, *P*=0.837, [Table 2](#T2){ref-type="table"}). Results of the meta-analyses are presented in [Table 2](#T2){ref-type="table"}.

![Forest plot of the association between *miR-146a* rs2910164 polymorphism and HNC risk (under homozygote model)](bsr-38-bsr20171342-g2){#F2}
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###### Meta-analysis on the association between *miR-146a* rs2910164 polymorphism and HNC risk

  Variables                     Study number   Statistic model   Test of heterogeneity   Test of association   Publication bias                             
  ----------------------------- -------------- ----------------- ----------------------- --------------------- ---------------------- ------------- ------- -------
  **Homozygote model**                                                                                                                                      
  ***Total***                   13             Fixed             0.226                   21.6                  1.113 (0.980--1.263)   0.099         1.000   0.793
  ***Ethnicity***                                                                                                                                           
  Caucasian                     5              Fixed             0.177                   36.7                  0.919 (0.716--1.180)   0.509                 
  Asian                         8              Fixed             0.541                   0                     1.189 (1.025--1.378)   **0.022**             
  ***Source of control***                                                                                                                                   
  Population-based study        3              Fixed             0.855                   0                     1.668 (1.183--2.352)   **0.004**             
  Hospital-based study          10             Fixed             0.471                   0                     1.113 (0.980--1.263)   0.603                 
  **Heterozygote model**                                                                                                                                    
  ***Total***                   13             Fixed             0.301                   14.2                  1.084 (0.991--1.186)   0.079         0.855   0.968
  ***Ethnicity***                                                                                                                                           
  Caucasian                     5              Fixed             0.076                   52.7                  1.040 (0.922--1.173)   0.521                 
  Asian                         8              Fixed             0.713                   0                     1.142 (0.997--1.308)   0.054                 
  ***Source of control***                                                                                                                                   
  Population-based study        3              Fixed             0.408                   3.5                   1.219 (0.974--1.526)   0.083                 
  Hospital-based study          10             Fixed             0.186                   40.5                  1.060 (0.961--1.169)   0.248                 
  **Dominant model**                                                                                                                                        
  ***Total***                   14             Fixed             0.282                   15.6                  1.088 (1.002--1.182)   **0.044**     0.661   0.549
  ***Ethnicity***                                                                                                                                           
  Caucasian                     6              Random            0.034                   58.6                  1.027 (0.857--1.232)   0.772                 
  Asian                         8              Fixed             0.959                   0                     1.155 (1.016--1.312)   **0.028**             
  ***Source of control***                                                                                                                                   
  Population-based study                       Fixed             0.674                   0                     1.359 (1.095--1.687)   **0.005**             
  Hospital-based study                         Fixed             0.462                   0                     1.047 (0.957--1.144)   0.318                 
  **Recessive model**                                                                                                                                       
  ***Total***                   13             Random            \<0.01                  66.3                  1.068 (0.896--1.272)   0.465         0.76    0.784
  ***Ethnicity***                                                                                                                                           
  Caucasian                     5              Fixed             0.344                   10.9                  0.919 (0.719--1.174)   0.449                 
  Asian                         8              Random            \<0.01                  76.5                  1.133 (0.914--1.404)   0.254                 
  ***Source of control***                                                                                                                                   
  Population-based study        3              Fixed             0.874                   0                     1.697 (1.367--2.107)   **\<0.001**           
  Hospital-based study          10             Fixed             0.204                   26                    0.941 (0.849--1.043)   0.247                 
  **Allele comparison model**                                                                                                                               
  ***Total***                   13             Random            0.002                   61                    1.061 (0.966--1.166)   0.214         0.855   0.587
  ***Ethnicity***                                                                                                                                           
  Caucasian                     5              Random            0.012                   69                    0.981 (0.814--1.183)   0.843                 
  Asian                         8              Random            0.021                   57.6                  1.103 (0.988--1.233)   0.082                 
  ***Source of control***                                                                                                                                   
  Population-based study        3              Fixed             0.991                   0                     1.394 (1.215--1.599)   **\<0.001**           
  Hospital-based study          10             Fixed             0.261                   19.8                  0.994 (0.935--1.056)   0.837                 

Values of *P*\<0.05 were considered statistically significant.

*miR-146a* C/G polymorphism and overall cancer risk {#sec3-3}
---------------------------------------------------

Furthermore, we explored the association between the pre-*miR-146a* C/G polymorphism and overall cancer risk. We first analyzed the heterogeneity by Q-test and *I*-squared in any of the genetic models. Significant statistical heterogeneity was identified in the homozygote model (*I*^2^ =57.1%, *P*~heterogneity~\<0.001), heterozygote model (*I*^2^ =55.1%, *P*~heterogneity~\<0.001), dominant model (*I*^2^ =46.4%, *P*~heterogneity~\<0.001), recessive model (*I*^2^ =60.9%, *P*~heterogneity~\<0.001), and allele comparison model (*I*^2^ =58.8%, *P*~heterogneity~\<0.001), so that random-effects model was used in all genetic models. Overall, significant association was not identified in all genetic models (homozygote model: OR =1.005, 95% CI =0.931--1.084, *P*=0901, [Figure 7](#F7){ref-type="fig"}; heterozygote model: OR =1.009, 95% CI =0.951--1.070, *P*=0.766, [Figure 8](#F8){ref-type="fig"}; dominant model: OR =0.998, 95% CI =0.951--1.047, *P*=0.932, [Figure 9](#F9){ref-type="fig"}; recessive model: OR =1.005, 95% CI =0.946--1.066, *P*=0.880, [Figure 10](#F10){ref-type="fig"}, and allele comparison model: OR =0.999, 95% CI =0.965--1.035, *P*=0.970, [Figure 11](#F11){ref-type="fig"}). Subgroup analysis was performed according to ethnicity. The same result was found, that is, no significant association was detected in all genetic models amongst Caucasians, Asians, and mixed populations. All the results are listed in [Table 3](#T3){ref-type="table"}.
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###### Meta-analysis on the association between *miR-146a* rs2910164 polymorphism and overall cancer risk

  Variables                     Study number   Statistic model   Test of heterogeneity   Test of association   Publication bias                       
  ----------------------------- -------------- ----------------- ----------------------- --------------------- ---------------------- ------- ------- -------
  **Homozygote model**                                                                                                                                
  ***Total***                   89             Random            \<0.001                 57.1                  1.005 (0.931--1.084)   0.901   0.568   0.889
  ***Ethnicity***                                                                                                                                     
  Caucasian                     28             Random            0.004                   46.9                  0.919 (0.716--1.180)   0.756           
  Asian                         60             Random            \<0.001                 61.4                  0.995 (0.915--1.083)   0.913           
  Mixed population              1              Random            \-                      \-                    1.01 (0.711--1.435)    0.956           
  ***Source of control***                                                                                                                             
  Population-based study        29             Random            \<0.001                 54.6                  1.134 (0.972--1.323)   0.109           
  Hospital-based study          60             Random            \<0.001                 55.4                  0.960 (0.882--1.045)   0.347           
  **Heterozygote model**                                                                                                                              
  ***Total***                   89             Random            \<0.001                 55.1                  1.009 (0.951--1.070)   0.766   0.918   0.836
  ***Ethnicity***                                                                                                                                     
  Caucasian                     28             Random            0.01                    42.7                  1.072 (0.902--1.273)   0.430           
  Asian                         60             Random            \<0.001                 59.3                  0.994 (0.934--1.057)   0.839           
  Mixed population              1              Random            \-                      \-                    0.957 (0.667--1.373)   0.812           
  ***Source of control***                                                                                                                             
  Population-based study        29             Random            \<0.001                 72.9                  1.013 (0.863--1.187)   0.878           
  Hospital-based study          60             Random            0.005                   35                    0.997 (0.944--1.052)   0.906           
  **Dominant model**                                                                                                                                  
  ***Total***                   89             Random            \<0.001                 46.4                  0.998 (0.951--1.047)   0.932   0.632   0.349
  ***Ethnicity***                                                                                                                                     
  Caucasian                     28             Random            0.003                   48                    1.012 (0.929--1.104)   0.781           
  Asian                         60             Random            \<0.001                 46.9                  0.989 (0.932--1.051)   0.731           
  Mixed population              1              Random            \-                      \-                    1.048 (0.887--1.240)   0.580           
  ***Source of control***                                                                                                                             
  Population-based study        29             Random            0.034                   35.1                  1.083 (0.983--1.168)   0.420           
  Hospital-based study          60             Random            \<0.001                 46.7                  0.957 (0.903--1.015)   0.143           
  **Recessive model**                                                                                                                                 
  ***Total***                   89             Random            \<0.001                 60.9                  1.005 (0.946--1.066)   0.880   0.975   0.817
  ***Ethnicity***                                                                                                                                     
  Caucasian                     28             Random            0.034                   35.1                  1.083 (1.003--1.168)   0.467           
  Asian                         60             Random            \<0.001                 46.7                  0.957 (0.903--1.015)   0.743           
  Mixed population              1              Random            \-                      \-                    0.989 (0.701--1.396)   0.951           
  ***Source of control***                                                                                                                             
  Population-based study        29             Random            \<0.001                 72.3                  1.041 (0.895--1.210)   0.605           
  Hospital-based study          60             Random            \<0.001                 50.3                  0.986 (0.929--1.046)   0.643           
  **Allele comparison model**                                                                                                                         
  ***Total***                   89             Random            \<0.001                 60.8                  0.999 (0.965--1.035)   0.970   0.790   0.757
  ***Ethnicity***                                                                                                                                     
  Caucasian                     28             Random            0.002                   49.8                  1.022 (0.954--1.095)   0.542           
  Asian                         60             Random            \<0.001                 65.1                  0.991 (0.950--1.032)   0.655           
  Mixed population              1              Random            --                      --                    1.030 (0.899--1.181)   0.670           
  ***Source of control***                                                                                                                             
  Population-based study        29             Random            \<0.001                 57.7                  1.053 (0.988--1.122)   0.112           
  Hospital-based study          60             Random            \<0.001                 60.1                  0.977 (0.938--1.017)   0.252           

Publication bias {#sec3-4}
----------------

Egger's test and Begg's test were used to investigate the publication bias in the literature in all the genetic models. No publication bias was detected by Begg's and Egger's tests. The shapes of the funnel plots (not shown) did not identify obvious asymmetry in any of the comparison models, and plot symmetries are evidenced by *P*-values greater than 0.05. Accordingly, no publication bias was evident in the meta-analysis ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

Sensitivity analysis {#sec3-5}
--------------------

We performed sensitivity analysis by sequential omission of individual studies, and the results showed that the significance of the pooled ORs for *miR-146a* rs2910164 polymorphism was not excessively influenced, suggesting the stability and reliability of the results in the present meta-analysis (not shown).

Discussion {#sec4}
==========

It is well known that genetic mutations are responsible for cancer occurrence \[[@B104]\]. SNPs, as the most common genetic sequence variation, could affect the function of a series of miRNAs by altering the formation of the primary transcript, miRNA maturation, or miRNA--mRNA interactions \[[@B105],[@B106]\]. Thus, genetic susceptibility to cancer, particularly from SNPs, has been a research focus in the scientific community. Previously, variations of the pre-*miR-146a* C/G gene have drawn increasing attention in cancer etiologies, and altered expression levels have been observed in inflammatory diseases as well as in cancers \[[@B107],[@B108]\]. The results of the present meta-analysis confirm that *miR-146a* C/G polymorphism is associated with HNC risk. This risk is significant amongst the individuals with a dominant genotype model. In the stratified analysis by ethnicity, significant analysis was detected amongst Asians under homozygote and dominant model, while no association was found amongst Caucasians under all genetic models. Furthermore, significant association was found in population-based studies under homozygote, dominant, recessive, and allele comparison models. However, no significant association was detected in hospital-based studies under all genetic models. Moreover, no significant association was found between this gene polymorphism and overall cancer risk. Furthermore, in the stratified analyses by ethnicity and source of control, no significant association was detected in the subgroup analyses of source of control.

To the best of our knowledge, the present study is the first and most comprehensive one to date to assess the relationship between *miR-146a* C/G polymorphism and HNC risk, and the most comprehensive one to date to explore the association between this gene polymorphism and overall cancer risk. Nevertheless, our meta-analysis also has some limitations common to these types of studies. First, relatively large heterogeneity was observed across all the studies involved despite the use of strict criteria for study inclusion and precise data extraction. So, we performed subgroup analyses to explore the possible source of heterogeneity. Second, the majority of subjects included in this meta-analysis were mainly Caucasians and Asians. Thus, the inherent genetic and geographic differences require more data from different ethnic group to increase the statistical power. Third, the low sample size in some of the included studies likely influences the statistical power for evaluating the association between the *miR-146a* C/G polymorphism and HNC risk, especially in subgroup analyses. Fourth, lack of original data from the reviewed studies limited our further evaluation of potential interactions, considering that gene-to-gene and gene-to-environment interactions might modulate cancer risk. As a result, a more precise analysis stratified by variable host factors could be performed. Last, although the results for publication bias were not statistically significant, publication bias may still exist, because only published studies were included in this meta-analysis.

In conclusion, the meta-analysis presented here indicates that *miR-146a* C/G polymorphism more is likely contribute to the susceptibility to HNC, and overall cancer risk. Further well-designed studies with large sample size are needed to confirm these findings.
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CI

:   confidence interval

HNC

:   head and neck cancer

HWE

:   Hardy--Weinberg equilibrium

OR

:   odds ratio

SNP

:   single nucleotide polymorphism
